Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (8) , 1363-1370
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsProceedings of the National Academy of Sciences of the United States of America, 2012
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesNature Biotechnology, 2012
- Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast CancerClinical Cancer Research, 2010
- Physicochemical Stability of the Antibody−Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation ProcessesBioconjugate Chemistry, 2010
- Antibody–drug conjugates: targeted drug delivery for cancerCurrent Opinion in Chemical Biology, 2010
- Protein Modification, Bioconjugation, and Disulfide Bridging Using BromomaleimidesJournal of the American Chemical Society, 2010
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- Anti-CD22-MCC-DM1 and MC-MMAF Conjugates: Impact of Assay Format on Pharmacokinetic Parameters DeterminationBioconjugate Chemistry, 2008
- Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometryProtein Science, 2005
- Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody DisulfidesBioconjugate Chemistry, 2005